Analysts' Actions: MU, NOK, X, AAPL, JPM

CHANGE IN RATINGS, EPS

Abbott Laboratories (ABT) rated new Buy at Jefferies. $60 price target. Fears of Humira competition are overdone.

Adobe Systems (ADBE) numbers lowered at ThinkEquity. Shares of ADBE now seen reaching $27. Estimates also cut, given slower growth in Europe. Hold rating.

Apple (AAPL) added to Best Ideas List at Wedbush. New $530 price target. Company should continue to see solid demand for the iPhone and iPad.

Bed Bath & Beyond (BBBY) estimates, target raised at UBS.Shares of BBBY now seen reaching $62. Estimates also increased on expected solid 2Q11 results. Neutral rating.

CBOE (CBOE) estimates, target boosted at Jefferies.Shares of CBOE now seen reaching $27. Estimates also upped, given higher expected volume growth. Hold rating.

Coventry Health (CVH) downgraded at Wedbush from Neutral to Underperform. $32 price target. Pricing cycle may be turning for the worse.

FedEx (FDX) estimates, target cut at Citigroup.Shares of FDX now seen reaching $95. Estimates also lowered as data points to slower growth. Buy rating.

FedEx estimates, target lowered at Dahlman Rose. FDX estimates were cut through 2013. Company is leveraged to slower economic growth. Buy rating and new $120 price target.

Hub Group (HUBG) estimates, target lowered at UBS. Shares of HUBG now seen reaching $32.50. Estimates also lowered on higher macro risk. Neutral rating.

Intercontinental Exchange (ICE) estimates upped at Jefferies. ICE estimates were boosted through 2012. Trading activity is improving. Buy rating and $145 price target.

JPMorgan Chase (JPM) rated new Overweight at Evercore. $46 pric! e target . Company can continue to gain market share.

Lennar (LEN) estimates lowered at Citigroup through 2012, Citigroup said. Macro risks and aggressive use of balance sheet. Maintain Hold rating.

Marvell Technology (MRVL) downgraded at JMP to Market Perform. Estimates also cut, as the company is facing potential growth headwinds.

MGM Resorts (MGM) upgraded at Morgan Stanley from Equal-weight to Overweight. $15 price target. Company is leveraged to improving leisure trends in Las Vegas.

Micron Technology (MU) estimates lowered at Sterne Agee through 2013. Company is leveraged to lower DRAM pricing. Buy rating and $14 price target.

Molycorp (MCP) downgraded at JP Morgan to Neutral. Estimates also cut, given uncertain pricing and demand. $66 price target.

Moody's (MCO) downgraded at Benchmark from Buy to Hold. $29 price target. Company will be hurt by the turbulent market environment.

Mosaic (MOS) upgraded at CIBC to Sector Outperform. Company is leveraged to higher potash prices. $88 price target.

Nasdaq OMX (NDAQ) estimates increased at Jefferies through 2012. Volumes trends are improving. Hold rating and $27 price target.

Nokia (NOK) estimates, target reduced at WedbushShares of NOK now seen reaching $6. Estimates also cut, as the company is losing market share. Neutral rating.

Progress Energy (PGN) rated new Outperform at BMO Capital. $18 price target. Company has a significant resource base and deserves a premium valuation.

Prudential (PRU) target cut at FBR to $66. Comp! any is b eing hurt by lower interest rates. Outperform rating.

PSS World Medical (PSSI) numbers reduced at Credit Suisse.Shares of PSSI now seen reaching $27. Estimates also cut, given lower utilization rates. Outperform rating.

Pulte Homes (PHM) upgraded at UBS from Neutral to Buy. $8 price target. Opportunities arise as new home market bottoms.

Salix Pharmaceutical (SLXP) estimates, target cut at UBS.Shares of SLXP now seen reaching $32. Estimates also lowered to reflect higher equity and fundamental risk. Neutral rating.

Tempur-Pedic (TPX) rated new Neutral at Goldman. Valuation call, based on a $66 price target.

US Steel (X) numbers reduced at Keybanc.Shares of X now seen reaching $45. Estimates also cut, given slower growth in Europe. Buy rating.

End of report.